Details of the Drug Combinations

General Information of This Drug (ID: DMQIMTK)

Drug Name

Ombitasvir DMQIMTK

Synonyms

2302768XJ8; ABT 267; ABT-267; ABT-267;ABT267;ABT 267; ABT267; CHEBI:85183; CHEMBL3127326; CS-5330; DB09296; Ombitasvir; Ombitasvir (USAN); Ombitasvir [USAN:INN]; Ombitasvir pound>>ABT-267; Ombitasvir(ABT-267); SB16895; SCHEMBL8542284; UNII-2302768XJ8; ZINC150601177; dimethyl ([(2S,5S)-1-(4-tert-butylphenyl)pyrrolidine-2,5-diyl]bis{(4,1-phenylene)carbamoyl(2S)pyrrolidine-2,1-diyl[(2S)-3-methyl-1-oxobutane-1,2-diyl]})biscarbamate

Indication

Disease Entry	ICD 11	Status	REF
Hepatitis C	1E51	Approved	[1]
------------------------------------------------------------------------------------

Therapeutic Class

Antiviral Agent

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

1 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Paritaprevir + Ombitasvir	DC3CYMQ	Paritaprevir	Hepatitis C Virus	[2]
------------------------------------------------------------------------------------

1 Approved Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Paritaprevir + Ombitasvir	DC2FWU4	Paritaprevir	Hepatitis C virus infection	[3]
------------------------------------------------------------------------------------

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2	ClinicalTrials.gov (NCT01458535) A Study to Evaluate Paritaprevir With Ritonavir (ABT-450/r) When Given Together With Ombitasvir and With and Without Ribavirin (RBV) in Treatment-Nave Participants With Genotype 1, 2 or 3 Chronic Hepatitis C Virus (HCV)
3	FDA Approved Drug Products from FDA Official Website. 2015. Application Number: (ANDA) 207931.